To date, several TKIs have been approved for the treatment of EGFR-mutated NSCLC, including first-generation (Erlotinib, Gefitinib), second-generation (Afatinib), and third-generation (Osimertinib) TKIs [8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.